Aprea Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Great. Good afternoon, everyone. My name is Jess Fye. I'm one of the senior biotech analysts at JPMorgan, and we're continuing the 2021 Healthcare Conference today with Aprea. I'm joined by the company's CEO, Chris Schade. (Operator Instructions)
So with that out of the way, let me turn it over to Chris.
Thanks, Jess, and happy new year. And on behalf of Aprea, I'd like to thank everyone for attending this afternoon and also to thank JPMorgan for the opportunity to present today.
If we move to Slide 2. Before beginning, I'd like to call everyone's attention to our forward-looking statements and refer you to our filings with the SEC, which explains the risks associated with our business.
Now moving forward to Slide 3. Aprea is the leader in developing novel anticancer therapeutics targeting the tumor suppressor protein, p53. Over the years, we've developed a wealth of preclinical
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |